Alterations in thyroid function in female sprague-dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin

C. H. Sewall, N. Flagler, John Patrick Vanden Heuvel, G. C. Clark, A. M. Tritscher, R. M. Maronpot, G. W. Lucier

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a multisite carcinogen. Although the hepatocarcinogenic actions of TCDD have received the most attention, it has been demonstrated in several rodent carcinogenicity bioassays that TCDD causes a dose-related increase in thyroid follicular cell adenomas and carcinomas. The purpose of the present experiment was to investigate the dose-response relationship for thyroid function alterations in female Sprague-Dawley rats following chronic treatment with TCDD. TCDD was administered via oral gavage biweekly for 30 weeks at average daily equivalent doses of 0.1-125 ng/kg/day, thereby more than encompassing the dose range historically used in previous TCDD rodent bioassays. The endpoints examined include serum levels of thyroxine (T4), triiodothyronine (T3), and thyroid-stimulating hormone (TSH). In addition, the induction of the dioxin-responsive genes UDP-glucuronosyltransferase-1 (UGT1) and cytochrome P450 1A1 (CYP1A1) in liver were measured using reverse-transcriptase-polymerase chain reaction (RT-PCR). In agreement with previous hypotheses, TCDD appears to alter thyroid function via a secondary mechanism, namely increased excretion of T4-glucuronide resulting from TCDD induction of UGT1. The observed follicular cell hyperplasia and hypertrophy are consistent with the observed elevated TSH levels and may represent the early stages in the progression of thyroid carcinogenesis. Therefore, TCDD induces alterations in thyroid hormone function, probably as a result of chronic perturbations of liver-pituitary-thyroid axis.

Original languageEnglish (US)
Pages (from-to)237-244
Number of pages8
JournalToxicology and Applied Pharmacology
Volume132
Issue number2
DOIs
StatePublished - Jan 1 1995

Fingerprint

Sprague Dawley Rats
Rats
Thyroid Gland
Glucuronosyltransferase
Bioassay
Triiodothyronine
Thyrotropin
Biological Assay
Liver
Rodentia
Polychlorinated Dibenzodioxins
1,4-dioxin
Dioxins
Polymerase chain reaction
RNA-Directed DNA Polymerase
Glucuronides
Reverse Transcriptase Polymerase Chain Reaction
Thyroxine
Thyroid Hormones
Carcinogens

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology

Cite this

Sewall, C. H. ; Flagler, N. ; Vanden Heuvel, John Patrick ; Clark, G. C. ; Tritscher, A. M. ; Maronpot, R. M. ; Lucier, G. W. / Alterations in thyroid function in female sprague-dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. In: Toxicology and Applied Pharmacology. 1995 ; Vol. 132, No. 2. pp. 237-244.
@article{a75cde2ca2b945dc9c4dddbd9cd87440,
title = "Alterations in thyroid function in female sprague-dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin",
abstract = "2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a multisite carcinogen. Although the hepatocarcinogenic actions of TCDD have received the most attention, it has been demonstrated in several rodent carcinogenicity bioassays that TCDD causes a dose-related increase in thyroid follicular cell adenomas and carcinomas. The purpose of the present experiment was to investigate the dose-response relationship for thyroid function alterations in female Sprague-Dawley rats following chronic treatment with TCDD. TCDD was administered via oral gavage biweekly for 30 weeks at average daily equivalent doses of 0.1-125 ng/kg/day, thereby more than encompassing the dose range historically used in previous TCDD rodent bioassays. The endpoints examined include serum levels of thyroxine (T4), triiodothyronine (T3), and thyroid-stimulating hormone (TSH). In addition, the induction of the dioxin-responsive genes UDP-glucuronosyltransferase-1 (UGT1) and cytochrome P450 1A1 (CYP1A1) in liver were measured using reverse-transcriptase-polymerase chain reaction (RT-PCR). In agreement with previous hypotheses, TCDD appears to alter thyroid function via a secondary mechanism, namely increased excretion of T4-glucuronide resulting from TCDD induction of UGT1. The observed follicular cell hyperplasia and hypertrophy are consistent with the observed elevated TSH levels and may represent the early stages in the progression of thyroid carcinogenesis. Therefore, TCDD induces alterations in thyroid hormone function, probably as a result of chronic perturbations of liver-pituitary-thyroid axis.",
author = "Sewall, {C. H.} and N. Flagler and {Vanden Heuvel}, {John Patrick} and Clark, {G. C.} and Tritscher, {A. M.} and Maronpot, {R. M.} and Lucier, {G. W.}",
year = "1995",
month = "1",
day = "1",
doi = "10.1006/taap.1995.1104",
language = "English (US)",
volume = "132",
pages = "237--244",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",
number = "2",

}

Alterations in thyroid function in female sprague-dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin. / Sewall, C. H.; Flagler, N.; Vanden Heuvel, John Patrick; Clark, G. C.; Tritscher, A. M.; Maronpot, R. M.; Lucier, G. W.

In: Toxicology and Applied Pharmacology, Vol. 132, No. 2, 01.01.1995, p. 237-244.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alterations in thyroid function in female sprague-dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin

AU - Sewall, C. H.

AU - Flagler, N.

AU - Vanden Heuvel, John Patrick

AU - Clark, G. C.

AU - Tritscher, A. M.

AU - Maronpot, R. M.

AU - Lucier, G. W.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a multisite carcinogen. Although the hepatocarcinogenic actions of TCDD have received the most attention, it has been demonstrated in several rodent carcinogenicity bioassays that TCDD causes a dose-related increase in thyroid follicular cell adenomas and carcinomas. The purpose of the present experiment was to investigate the dose-response relationship for thyroid function alterations in female Sprague-Dawley rats following chronic treatment with TCDD. TCDD was administered via oral gavage biweekly for 30 weeks at average daily equivalent doses of 0.1-125 ng/kg/day, thereby more than encompassing the dose range historically used in previous TCDD rodent bioassays. The endpoints examined include serum levels of thyroxine (T4), triiodothyronine (T3), and thyroid-stimulating hormone (TSH). In addition, the induction of the dioxin-responsive genes UDP-glucuronosyltransferase-1 (UGT1) and cytochrome P450 1A1 (CYP1A1) in liver were measured using reverse-transcriptase-polymerase chain reaction (RT-PCR). In agreement with previous hypotheses, TCDD appears to alter thyroid function via a secondary mechanism, namely increased excretion of T4-glucuronide resulting from TCDD induction of UGT1. The observed follicular cell hyperplasia and hypertrophy are consistent with the observed elevated TSH levels and may represent the early stages in the progression of thyroid carcinogenesis. Therefore, TCDD induces alterations in thyroid hormone function, probably as a result of chronic perturbations of liver-pituitary-thyroid axis.

AB - 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a multisite carcinogen. Although the hepatocarcinogenic actions of TCDD have received the most attention, it has been demonstrated in several rodent carcinogenicity bioassays that TCDD causes a dose-related increase in thyroid follicular cell adenomas and carcinomas. The purpose of the present experiment was to investigate the dose-response relationship for thyroid function alterations in female Sprague-Dawley rats following chronic treatment with TCDD. TCDD was administered via oral gavage biweekly for 30 weeks at average daily equivalent doses of 0.1-125 ng/kg/day, thereby more than encompassing the dose range historically used in previous TCDD rodent bioassays. The endpoints examined include serum levels of thyroxine (T4), triiodothyronine (T3), and thyroid-stimulating hormone (TSH). In addition, the induction of the dioxin-responsive genes UDP-glucuronosyltransferase-1 (UGT1) and cytochrome P450 1A1 (CYP1A1) in liver were measured using reverse-transcriptase-polymerase chain reaction (RT-PCR). In agreement with previous hypotheses, TCDD appears to alter thyroid function via a secondary mechanism, namely increased excretion of T4-glucuronide resulting from TCDD induction of UGT1. The observed follicular cell hyperplasia and hypertrophy are consistent with the observed elevated TSH levels and may represent the early stages in the progression of thyroid carcinogenesis. Therefore, TCDD induces alterations in thyroid hormone function, probably as a result of chronic perturbations of liver-pituitary-thyroid axis.

UR - http://www.scopus.com/inward/record.url?scp=0029038565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029038565&partnerID=8YFLogxK

U2 - 10.1006/taap.1995.1104

DO - 10.1006/taap.1995.1104

M3 - Article

C2 - 7540335

AN - SCOPUS:0029038565

VL - 132

SP - 237

EP - 244

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

IS - 2

ER -